文献速递肝病消化内镜

原发性硬化性胆管炎患者主导性狭窄的预定内镜下扩张对结局的影响

Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis.
PubMed 文献 · Gut · 2019-03-25

该回顾性研究纳入1987至2017年286例原发性硬化性胆管炎患者,比较按计划定期内镜逆行胰胆管造影扩张主导性狭窄与按需内镜治疗。中位随访9.9年,预定扩张组无移植生存率51% vs 29.3%(p<0.001),无移植生存时间中位17.9 vs 15.2年(log-rank p=0.008),获益仅在诊断时或随访中发现主导性狭窄的患者中显著。

要点

  • 预定内镜扩张组无移植生存率51% vs 按需组29.3%(p<0.001)。
  • 无移植生存时间中位17.9 vs 15.2年(log-rank p=0.008)。
  • 获益仅在初始或随访诊断主导性狭窄患者中显著(17.8 vs 11.1年,log-rank p<0.001)。

核心结论

  • 在这项大型回顾性研究中,定期内镜逆行胰胆管造影联合内镜球囊扩张可显著获益于伴有主导性狭窄的原发性硬化性胆管炎患者,无论狭窄在初诊时还是监测期间诊断,即使无症状。
  • 需进一步研究以找到无创识别狭窄患者的最佳方法。

研究设计与样本

  • 1987年至2017年间,所有新发原发性硬化性胆管炎患者被提供预定内镜逆行胰胆管造影,若诊断主导性狭窄则进行扩张,并按既定间隔重复直至形态学缓解,独立于临床症状(治疗组)。
  • 拒绝参与的患者每年临床评估,仅按需接受内镜治疗(对照组)。
  • 最终纳入286例患者,133例(46.5%)接受预定内镜逆行胰胆管造影,153例(53.5%)接受按需内镜逆行胰胆管造影。

主要发现

  • 平均随访9.9年后,预定内镜逆行胰胆管造影组无移植生存率高于按需组(51% vs 29.3%;p<0.001)。
  • 无移植生存时间中位预定组17.9年 vs 按需组15.2年(log-rank p=0.008)。
  • 预定内镜逆行胰胆管造影的获益仅在初始(17.1%)或后续(45.5%)诊断主导性狭窄的患者中显著(17.8 vs 11.1年;log-rank p<0.001)。
  • 炎症性肠病(p=0.03)、主导性狭窄(p=0.006)、较高Mayo风险评分(p=0.02)和不遵守预定内镜检查(p=0.005)与无移植生存独立相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Scheduled endoscopic dilatation of dominant strictures (DS) in primary sclerosing cholangitis (PSC) might improve outcome relative to endoscopic treatment on demand, but evidence is limited. Since randomisation is difficult in clinical practice, we present a large retrospective study comparing scheduled versus on-demand endoscopic retrograde cholangiopancreatography (ERCP) based on patient preferences. DESIGN: Between 1987 and 2017, all new patients with PSC had been offered scheduled ERCP with dilatation of a DS if diagnosed; the latter was repeated at defined intervals until morphological resolution, independent of clinical symptoms (treatment group). Patients who refused participation were clinically evaluated annually and received endoscopic treatment only on demand (control group). The primary clinical endpoint was transplantation-free survival. Secondary outcomes were overall survival, bacterial cholangitis episodes, hepatic decompensation of liver cirrhosis and endoscopy-related adverse events. RESULTS: The final study included 286 patients, 133 (46.5%) receiving scheduled ERCP and 153 (53.5%) receiving on-demand ERCP. After a mean follow-up of 9.9 years, the rate of transplantation-free survival was higher in patients receiving scheduled ERCP (51% vs 29.3%; p<0.001), as was transplantation-free survival time (median: 17.9 vs 15.2 years; log-rank: p=0.008). However, the benefit of scheduled ERCP was significant only in patients with the initial (17.1%) or later (45.5%) diagnosis of a DS (17.8 vs 11.1 years; log-rank: p<0.001). IBD (p=0.03), DS (p=0.006), higher Mayo Risk Score (p=0.02) and non-adherence to scheduled endoscopy (p=0.005) were independently associated with transplantation-free survival. CONCLUSION: In our large retrospective study, regular ERCP with endoscopic balloon dilatation significantly benefits patients with PSC with DS, diagnosed both at initial presentation and during surveillance, even if asymptomatic. Further studies have to find out how to best identify stricture patients non-invasively.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Rupp C, Hippchen T, Bruckner T, et al. Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis. Gut. 2019. PMID: 30910856. doi:10.1136/gutjnl-2018-316801

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。